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Abstract
Background: Interleukin-33 (IL-33) is a cytokine belonging to the IL-1 family, and its possible involvement in the
pathophysiology of COPD and viral-induced exacerbations has been demonstrated. IL-33 has been shown to be
increased in the airway epithelial cells from COPD patients, but the regulating mechanism of IL-33 expression in
airway epithelial cells remains largely unknown. In the current study, we examined whether oxidative stress, which
participates in the pathogenesis of COPD, affects the expression of IL-33 in airway epithelial cells and also evaluated
the effect during viral infection.
Methods: The involvement of oxidative stress in the expression of IL-33, and its signal pathway was examined after
stimulation with hydrogen peroxide (H2O2), with or without stimulation by polyinosinic-polycytidylic acid [poly (I:C)], a
synthetic analogue of dsRNA that mimics viral infection, or rhinovirus infection in NCI-H292 cells and primary human
bronchial epithelial cells (HBECs). In addition, the effect of antioxidant, N-acetylcysteine (NAC) in the expression of IL-33
was compared between HBECs from healthy subjects and those from COPD patients.
Results: Treatment with H2O2 significantly potentiated IL-33 expression in NCI-H292 cells, and the potentiation was
reversed by NAC treatment. Mitogen-activated protein kinase (MAPK) inhibitors, but not nuclear factor-kappa B inhibitors,
also significantly decreased the H2O2-potentiated IL-33 expression. In addition, H2O2 significantly potentiated the poly
(I:C)- or rhinovirus-stimulated IL-33 expression. In HBECs from healthy subjects, H2O2-potentiated IL-33 expression and its
reversal by NAC was also confirmed. Under the condition without H2O2-stimulation, treatment with NAC significantly
decreased the expression of IL-33 in HBECs from COPD patients, but not in those from healthy subjects.
Conclusions: These results demonstrate that oxidative stress involves in the expression of IL-33 in airway epithelial cells
via MAPK signal pathway and it augments IL-33 expression during viral infection. This mechanism may participate in the
regulation of IL-33 expression in airway epithelial cells in COPD and the viral-induced exacerbations. Modulation of this
pathway could become a therapeutic target for viral-induced exacerbations of COPD.
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Background
Chronic obstructive pulmonary disease (COPD) was
ranked sixth as a cause of death in 1990, but it is cur-
rently the third leading cause of death in the world [1].
Exacerbations of COPD triggered by respiratory infec-
tions or environmental pollutants cause an acute deteri-
oration in airway inflammation and lung function, and
also lead to an increase in mortality and healthcare costs
[2–5]. The prevention of exacerbations remains a key
therapeutic goal, but current treatments have only mod-
est benefits and considerable adverse effects. Therefore,
since new treatments are urgently needed, a better un-
derstanding of the mechanisms of COPD exacerbations
is needed.
Interleukin-33 (IL-33) is a cytokine belonging to the IL-1
family, which includes IL-1α, IL-1β and IL-18. It is mainly a
nuclear protein in several types of cells including endothe-
lial cells, epithelial cells and fibroblasts [6, 7]. Once released
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into the extracellular compartment in response to tissue
damage or inflammation, extracellular IL-33 has been
shown to act as a potent inducer of inflammation [6, 7]. Es-
pecially, IL-33 promotes T helper 2 cell (Th2) immunity,
which leads to allergic pathological changes via ST2 recep-
tor, a member of the IL-1/Toll-like receptor family [8]. IL-
33 has been extensively characterized as functionally im-
portant in Th2-associated inflammatory diseases including
asthma, atopic dermatitis and helminth infections [6]. Al-
though higher expression of IL-33 has been reported in pa-
tients with asthma [9], it has also been demonstrated in
bronchial epithelial cells from those with COPD, especially
in a severe stage of COPD [10, 11]. In a COPD mouse
model and in vitro airway epithelial cells, increases of IL-33
have been also shown, especially during viral infection or
after cigarette smoke exposure [11]. Despite the increasing
evidence suggesting the contribution of IL-33 to the patho-
physiology of COPD and its exacerbations [12], the regulat-
ing mechanism of the expression of IL-33 in airway
epithelial cells remains largely unknown.
Reactive oxygen species (ROS), including hydrogen
peroxide (H2O2) derived from cigarette smoke or re-
leased by inflammatory cells, are reported to contribute
to the pathogenesis of COPD and its exacerbations [13,
14]. In fact, oxidative stress markers such as H2O2 are
elevated in the airways of COPD patients [15–18], and
higher amounts of H2O2 are detected in the airways dur-
ing the exacerbations than in those in a stable condition
[19, 20]. Pretreatment with H2O2 has been reported to
augment the production of pro-inflammatory cytokines
and chemokines in airway epithelial cells and inflamma-
tory cells [21, 22]. Our previous report has also demon-
strated that H2O2 augments viral-derived double-
stranded RNA (dsRNA)-stimulated CXC motif chemo-
kine ligand (CXCL) 8 release in human airway epithelial
cells via the activation of Toll-like receptor 3 (TLR3) sig-
nal pathway [23]. Concerning IL-33, an antioxidant, N-
acetylcysteine (NAC) or glutathione (GSH), has been re-
ported to inhibit the alternaria extract-augmented IL-33
release in an allergic mouse model, which suggests the
possible involvement of oxidative stress in the regulation
of IL-33 production [24]. However, it has not been deter-
mined whether oxidative stress affects the expression of
IL-33 and which signal pathways are participated in the
regulating mechanisms in airway epithelial cells.
The present study, therefore, was designed to determine,
using H2O2 and an experimental viral infection model, the
following: (1) whether oxidative stress potentiates IL-33
expression in human airway epithelial cells and which sig-
nal pathways participate in the regulating mechanisms; (2)
whether oxidative stress augments IL-33 expression in the
dsRNA-treated or viral infected cells; and (3) whether
antioxidant treatment decreases the expression of IL-33 in
airway epithelial cells from COPD patients.
Methods
Materials
Poly (I:C) (polyinosinic-polycytidylic acid, sodium salt,
double-stranded), SB203580, SP600125, U0126, SC-514
and BAY 11-7085 were purchased from Calbiochem (La
Jolla, CA). H2O2, NAC and 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenylterazolium bromide (MTT) were from
Sigma-Aldrich (St. Louis, MO).
Patients
Five never smokers and six former smokers with COPD
took part in our study after giving written informed con-
sent (Table 1). COPD was diagnosed according to the
GOLD guidelines [25]. All subjects had undergone sur-
gery for lung cancer after receiving pulmonary function
tests. Human bronchial tissues were obtained from the
2-4 bronchi of the lobe resected at surgery, avoiding
areas involved by tumors. The tissues were used for the
culture of human bronchial cells. All experiments in the
study were approved by the ethics committee of Tohoku
University Graduate School of Medicine.
Preparation of epithelial cells
NCI-H292 cells, a human pulmonary mucoepidermoid
carcinoma cell line (ATCC, Manassas, VA) and primary
human bronchial epithelial cells (HBECs), acquired from
lobes resected from patients at surgery, the details of
which are shown in Table 1, were cultured as previously
described [26]. Cells were grown to 80% confluence in
culture plates and incubated in fetal bovine serum
(FBS)- or growth factor-free medium for 24 h before
treatment.
To investigate the effect of H2O2 on the expression of IL-
33, the cells were harvested at 4 h, unless indicated other-
wise, after treatment with H2O2 and stored at − 80 °C until
the measurement. To examine the effect of H2O2 on the poly
Table 1 Characteristics of healthy subjects and patients with
COPD
Healthy subjects COPD
Number 5 6
Male/Female 1/4 5/1
Age (years) 68.0 ± 3.4 68.0 ± 3.8
Ex-smoker/current smoker 0/0 6/0
Pack years N/A 45.6 ± 8.5**
Lung function
FEV1/FVC (%) 86.8 ± 3.3 62.7 ± 3.0***
FEV1% of predicted (%) 108 ± 6.7 75.5 ± 6.7**
DLCO/VA (%) 114 ± 4.2 85.2 ± 3.7***
Data are presented as mean ± SEM
**, *** represents, p < 0.01, p < 0.001 vs. healthy subjects
Abbreviations: COPD chronic obstructive pulmonary disease, FEV1 forced
expiratory volume in 1 s, FVC forced vital capacity, DLCO/VA corrected carbon
monoxide diffusing capacity by alveolar volume, N/A not applicable
Aizawa et al. Respiratory Research  (2018) 19:52 Page 2 of 12
(I:C) or rhinovirus infection-induced IL-33 expression, H2O2
was added to the media 30 min before the treatment with
poly (I:C) or rhinovirus [23]. To evaluate the effects of inhibi-
tors, various concentrations of NAC, p38-MAPK inhibitor
(SB203580), JNK inhibitor (SP600125), ERK inhibitor
(U0126), IKK-2 inhibitor (SC-514) or IκBα inhibitor (BAY11-
7085) were added to the media 1 h before H2O2 treatment
[27, 28]. In the control group, the cells were treated with
medium in the absence of H2O2, poly (I:C), or inhibitors.
Rhinovirus infection
A stock solution of type 14 rhinovirus (RV14) [1.0 × 107
tissue culture infectious dose (TCID50)/ ml] was
obtained from a patient with a common cold and the
rate of RV14 release was quantified in the same manner
as previously described in methods [29]. NCI-H292 cells
in culture plates were infected with RV14 at a multipli-
city of infection (MOI) of 1 for 90 min in RPMI-1640
medium at 33 °C before the virus was removed and re-
placed with RPMI-1640 medium [26, 30, 31]. NCI-H292
cells were treated with H2O2 or vehicle 30 min prior to
RV14 infection. Cells were infected with RV14 for
90 min and the virus was removed and replaced with
medium containing 200 μM H2O2 or vehicle. In some
experiments, cells were pretreated with NAC 1 h prior
to infection. After the cells were incubated for 1 to 48 h
at 33 °C, the whole cell extractions were harvested and
stored at − 80 °C until required.
Cell viability assay
Cell viability in NCI-H292 cells were evaluated by use of
the MTT assay and in HBECs were evaluated by the lac-
tate dehydrogenase (LDH) activity using Cytotoxicity
Detection KitPLUS (Sigma-Aldrich) as previously de-
scribed [26]. Cell viability was calculated as the percent-
age of viable cells among vehicle-treated cells.
Detection of mitogen-activated protein kinase (MAPK)
phosphorylation by immunoblotting
Cells were seeded in 6-well plates at a density of 1 × 105/
ml. At 80% confluence, and maintained in FBS-free
medium for 24 h before stimulation. To evaluate the
inhibitory effect of NAC on the expression of phospho-
p38 (p-p38), c-jun N-terminal kinase (p-JNK) and Extra-
cellular Signal-regulated Kinase 1/2 (p-ERK1/2), the cells
were treated with NAC 60 min prior to H2O2 stimula-
tion. After 15 min H2O2 stimulation, cells were washed
with ice-cold HANK’s balanced salt solution (HBSS) and
homogenized in cell lysis buffer (0.05% TritonX, 35 mM
Tris-HCl, pH 7.4, 0.4 mM EGTA, 10 mM MgCl2, 1 μM
phenylmethylsulfonyl fluoride, 100 μg/ml aprotinin and
1 μg/ml leupeptin) at 4 °C. Samples were solubilized in
sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE)
sample buffer. Equal amounts of protein were loaded
and the separated by electrophoresis on 12.5% SDS-
PAGE. After electrophoresis, the separated proteins were
blotted on a PolyVinylidene DiFluoride (PVDF) mem-
brane (Bio-Rad Laboratories, Herculer, CA). Rabbit
monoclonal anti-phospho-p38 MAPK antibody, rabbit
monoclonal anti-p38 MAPK antibody, rabbit monoclo-
nal anti-phospho-JNK antibody, rabbit monoclonal anti-
JNK antibody, rabbit polyclonal anti-phospho-ERK1/2
antibody, rabbit polyclonal anti-ERK1/2 antibody (1:1000
dilution, all from Cell Signaling Technology, Danvers,
MA) and mouse monoclonal anti–β-actin antibody (1:
10000 dilution; Sigma) were used to detect the target
proteins. Appropriate peroxidase-conjugated secondary
antibodies were used. Binding antibodies were detected
using ECL-prime (Amersham Biosciences, Buckingham-
shire, UK) and visualized with a chemiluminescence im-
aging system (LAS-4000 mini; Fujifilm, Tokyo, Japan).
Each band intensity was quantified by densitometry
(Quantity One software, Bio-Rad).
Detection of IL-33 by nuclear extraction and
immunoblotting
Cells were treated with 200 μM H2O2 for 0 to 12 h.
After washing with HBSS, cells were homogenized in
cell lysis buffer to obtain the nuclear fraction using Nu-
clear Extraction Kit (Active Motif, Carlsbad, CA) accord-
ing to the manufacturer’s instructions. The following
separation, blotting, detection and visualization proce-
dures were performed in the same manner as for MAPK
phosphorylation immunoblotting. Target proteins were
detected with mouse monoclonal anti-IL-33 antibody (1:
1000 dilution, Enzo Life Sciences, Exeter, UK) or mouse
monoclonal anti-lamin A/C antibody (1:400 dilution;
Santa Cruz Biotechnology, Santa Cruz, CA).
Real-time polymerase chain reaction (PCR)
Total RNA was isolated from the cells to prepare
cDNA using High capacity of RNA to cDNA kit (Ap-
plied Biosystems, Foster City, CA) according to the
manufacturer’s instructions. cDNA was amplified with
specific primers to IL-33 and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) using the 7500 Real-
Time PCR System (Applied Biosystems). Primers used
to amplify cDNA were from TaqMan Gene Expres-
sion Assays (Applied Biosystems): IL-33 (catalogue
number Hs00369211_m1), GAPDH (Hs99999905_ml).
Relative quantification of different transcripts was de-
termined with the comparative threshold cycle (CT)
method using GAPDH as the endogenous control.
Results were calculated as fold change over control.
Statistical analysis
Data are expressed as the mean ± SEM. GraphPad Prism
(GraphPad Software Inc., SanDiego, CA) was used to
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perform statistical tests. Experiments with multiple com-
parisons were evaluated using one way analysis of vari-
ance (ANOVA) by Bonferroni’s test to adjust for
multiple comparisons. Wilcoxon matched-pairs signed
rank test or Mann-Whitney U test was used for single
comparison. Significance values were defined as p < 0.05.
Results
Effect of H2O2 on the expression of IL-33 in NCI-H292 cells
NCI-H292 cells, a human pulmonary mucoepidermoid
carcinoma cell line, have been used for evaluation of the
pathophysiology in obstructive airway disease, especially
as a model for mucin production, which is one of the
main features of COPD [26, 27]. NCI-H292 cells share key
components of various signaling pathways including
MAPK and nuclear factor-kappa B (NF-κB) with normal
HBECs and have been used to evaluate the involvement of
oxidative stress in cytokine release and mucus secretion
[27, 32, 33]. Here, we used NCI-H292 cells to clarify the
involvement of oxidative stress in the expression of IL-33
in the airway epithelial cells and we investigated the effect
of H2O2 on the expression of IL-33 in NCI-H292 cells.
Treatment with H2O2 significantly increased the expres-
sion of IL-33 at concentrations of 0 to 200 μM in a
concentration-dependent manner without affecting the
cell viability (Fig. 1a-b). In addition, the H2O2-potentiated
IL-33 expression reached the peak at 4 h and the potenti-
ated expression decreased at 24 h to the same as that at
0 h (Fig. 1c). We also confirmed that H2O2 significantly
increased the concentration of IL-33 protein in the com-
partment of nuclei in the treated cells at 12 h (Fig. 1d-e).
To clarify the involvement of oxidative stress in H2O2-po-
tentiated IL-33 expression, the effect of NAC was evalu-
ated. Pretreatment with 1 to 10 mM NAC significantly
decreased the H2O2-potentiated IL-33 expression in a
concentration-dependent manner (Fig. 1f).
Involvement of MAPK (p38, JNK, ERK1/2) and NF-κB
signaling pathways in H2O2-potentiated IL-33 expression
Previous reports indicated that oxidative stress induced
the activation of MAPK [p38 MAPK, JNK, ERK1/2] and
NF-κB [23, 28, 34]. Therefore, we investigated whether
the potentiated effect of H2O2 on IL-33 expression is
mediated by MAPK and NF-κB signaling pathways in
NCI-H292 cells. Treatment with H2O2 significantly in-
creased the phosphorylation of p38-MAPK, JNK and
ERK1/2 (Fig. 2a). The H2O2-augmented phosphorylation
of MAPK was inhibited by pretreatment with 10 mM
NAC (Fig. 2a-d). Pretreatment with MAPK inhibitor, a
p38 MAPK inhibitor, SB203580, a JNK inhibitor,
SP600125, or an ERK1/2 inhibitor, U0126, inhibited the
phosphorylation of p38-MAPK, JNK and ERK1/2 re-
spectively (Additional file 1: Figure S1A-C) and dose-
dependently inhibited the H2O2-augmented IL-33 mRNA
expression in the cells without affecting the cell viability
(Fig. 2e-g). On the other hand, pretreatment with NF-κB
inhibitor (an IKK-2 inhibitor, SC-514, or an IκBα inhibitor,
BAY 11-7085) did not inhibit the H2O2-augmented IL-33
expression (Additional file 1: Figure S2A-B).
Effect of H2O2 on a synthetic viral dsRNA analogue, poly
(I:C)- or viral-potentiated IL-33 expression
Rhinovirus infection is thought to be a key factor and an
important modulator of COPD exacerbations [35, 36]. In
our previous study, we confirmed that TLR3 was
expressed in NCI-H292 cells, and poly (I:C), which is a
synthetic viral dsRNA analogue and a TLR3 ligand to
mimic viral infection, activated TLR3 [26, 27]. To deter-
mine whether oxidative stress augments IL-33 expres-
sion during viral infection, we investigated the effect of
H2O2 on the expression of IL-33 in poly (I:C)-treated
NCI-H292 cells. H2O2 slightly but significantly aug-
mented the expression of IL-33 in the poly (I:C)-treated
cells (Fig. 3a). The augmentation was significantly inhib-
ited by 10 mM NAC treatment (Fig. 3b). To confirm
that the augmented effect observed with poly (I:C) could
be replicated by a virus, we performed further experi-
ments using human rhinovirus, RV14. RV14 infection
slightly but significantly increased the expression of IL-33
in NCI-H292 cells after 4 h RV14 treatment (Fig. 4a-b). In
the experimental protocol for viral infection, 200 μM
H2O2 was added two times to medium 30 min prior to
RV14 treatment and after 90 min incubation with RV14
to remove the RV14 from the supernatant and replace the
medium. In this condition, H2O2 -potentiated IL-33
mRNA expression reached a peak at 24 h, but not at 4 h,
at which point H2O2 single treatment caused the peak in
Fig. 1c (Fig. 4a). Treatment with H2O2 potentiated the ex-
pression of IL-33 in the RV14-infected cells and the
H2O2-potentiated IL-33 expression reached a peak at 24 h
(Fig. 4a). After 24 h RV14 infection, H2O2 significantly
augmented IL-33 expression in RV14-infected cells (Fig.
4b). In addition, the augmentation was significantly inhib-
ited by 10 mM NAC treatment (Fig. 4c).
Involvement of oxidative stress in the expression of IL-33
in HBECs from COPD patients
In HBECs from healthy subjects, H2O2 also significantly
increased the expression of IL-33 and the H2O2-aug-
mented IL-33 expression was inhibited by pretreatment
with 10 mM NAC (Fig. 5a). To clarify the involvement
of oxidative stress in the expression of IL-33 in the air-
way epithelial cells from COPD patients, we examined
the effect of an antioxidant, NAC on the expression of
IL-33 in HBECs from healthy subjects and age-matched
COPD patients. Under the condition without H2O2-
stimulation, pretreatment with 10 mM NAC significantly
decreased the expression of IL-33 in HBECs from COPD
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patients, but not in those from healthy subjects (Fig. 5b).
On the other hand, concerning the basal expression of
IL-33 in the airway epithelial cells, there was no increase
in the expression of IL-33 in HBECs from COPD pa-
tients compared to those from healthy subjects (data not
shown). In addition, to clarify the involvement of MAPK
signaling pathways in the expression of IL-33 in HBECs
from COPD patients, we examined the effect of MAPK
inhibitor, a p38 MAPK inhibitor, SB203580, a JNK in-
hibitor, SP600125 and an ERK1/2 inhibitor, U0126, on
the expression of IL-33 in HBECs from COPD patients.
Under the condition without H2O2-stimulation, pretreat-
ment with SB203580, SP600125 or U0126, significantly
decreased the expression of IL-33 in HBECs from COPD
patients (Fig. 5c-e).
Cell viability
The effects of the treatments on cell viability were
assessed with the MTT assay in NCI-H292 cells and
with the LDH assay in HBECs. Cell viability in the NCI-
H292 cells was more than 77.2% after the treatment with
H2O2, excluding the concentration at 500 μM, poly (I:C)
, rhinovirus infection and the inhibitors. In the HBECs,
cell viability was more than 79.8% after the treatment
with H2O2 and NAC.
Discussion
In the current study, we demonstrated that H2O2 potenti-
ated the expression of IL-33 in NCI-H292 cells and pri-
mary HBECs and clarified the involvement of MAPK
signal pathway by showing that inhibition of p38 MAPK,
Fig. 1 Effect of H2O2 on the expression of Interleukin-33 (IL-33) in NCI-H292 cells. a-c Effect of H2O2 on the gene expression of IL-33 and the cell viability
in NCI-H292 cells. a, b Cells were treated with various concentration of H2O2. After 4 h incubation, whole cells were harvested and assayed for the gene
expression of IL-33 (a) and cell viability (b). c Cells were treated with 200 μM H2O2. At various time points after the incubation, whole cells were harvested
and assayed. d, e Evaluation of nuclear fraction of IL-33 protein. At various time points after the treatment with 200 μM H2O2, the nuclear fraction of cell
lysates was obtained. d IL-33 protein in the nuclear fraction was evaluated by immunoblotting. e Each band intensity was assessed by densitometry.
Relative intensity was calculated by dividing the IL-33 band intensity by each appropriate lamin A/C band intensity. f Effect of N-acethylcysteine (NAC) on
H2O2-augmented IL-33 expression. Values are the mean ± SEM (n= 3 - 5). *p< 0.05, ***p< 0.001 compared with the values of vehicle-treated cells
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JNK or ERK1/2 reversed the H2O2-augmented IL-33 ex-
pression. We also showed that pretreatment with H2O2
augmented the expression of IL-33 in a TLR3 ligand, poly
(I:C)-treated cells and rhinovirus-infected cells. These re-
sults suggested that oxidative stress is involved in the ex-
pression of IL-33 in airway epithelial cells via MAPK
signal pathway and the expression of IL-33 could be fur-
ther increased in the airway epithelial cells during virus
infections, which is a main cause of COPD exacerbations
(Fig. 6). In addition, we demonstrated that NAC treatment
decreased the expression of IL-33 in HBECs from COPD
patients, which suggested that oxidative stress was in-
volved in the expression of IL-33 in HBECs from these pa-
tients. Although a previous study suggested the possible
involvement of oxidative stress in the regulation of IL-33
production in an allergic mouse model [24], here, we
Fig. 2 Involvement of mitogen-activated protein kinase signaling pathways in H2O2-potentiated IL-33 expression. a-d Effect of H2O2 on the
phosphorylation of MAPK (p38, JNK, ERK1/2) in NCI-H292 cells. Cells were treated with NAC or vehicle prior to treatment with H2O2. After 15 min,
whole cell lysates were obtained. a Phosphorylation of p38, JNK or ERK was evaluated with immunoblotting. b-d Band intensities were assessed
by densitometry. Relative intensity was calculated by dividing the phosphorylated p38, JNK or ERK1/2 band intensity by the p38, JNK or ERK1/2
band intensity and the results were indicated as fold change over control. e-g Effect of p38-MAPK inhibitor (SB203580) (e), JNK inhibitor
(SP600125) (f) or ERK inhibitor (U0126) (g) on H2O2-potentiated IL-33 expression in NCI-H292 cells. Values are the mean ± SEM (n = 3). **p < 0.01,
***p < 0.001 compared with the values of vehicle-treated cells
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demonstrated that exogenous H2O2 treatment potentiates
the expression of IL-33 in human airway epithelial cells
via MAPK signaling. In addition, we demonstrated the
possibility that oxidative stress augments the expression of
IL-33 during viral infection and is involved in the
expression of IL-33 in HBECs from COPD patients.
Modulation of this pathway could be a therapeutic target
for viral-induced exacerbations of COPD.
In the present study, we showed that exogenous H2O2
treatment potentiates the expression of IL-33 in NCI-
Fig. 4 Effect of H2O2 on viral-potentiated IL-33 expression. Time course (a) or comparison at 4 and 24 h (b) of IL-33 expression after treatment
with H2O2 and human rhinovirus, RV14 infection. NCI-H292 cells were infected with RV14 in the presence of H2O2 or vehicle. At various time
points after incubation (a) or after 4 and 24 h (b), whole cells were harvested and assayed for the IL-33 gene expression. c Effect of NAC on
H2O2-augmented IL-33 expression in RV14-treated cells. Cells were added with NAC before H2O2 treatment, and then infected with RV14. After
24 h RV14 infection, whole cells were harvested and assayed. Values are the mean ± SEM (n = 2 - 5). *p < 0.05, **p < 0.01, ***p < 0.001 compared
with the values of vehicle-treated cells
Fig. 3 Effect of H2O2 on a synthetic viral dsRNA analogue, poly (I:C)-potentiated IL-33 expression. a NCI-H292 cells were treated with H2O2 or
vehicle 30 min prior to the treatment with poly (I:C). After 4 h, whole cells were harvested and assayed for the IL-33 gene expression. b Effect
of NAC on H2O2-augmented IL-33 expression in poly (I:C)-treated cells. Cells were added with NAC before H2O2 treatment, and then treated with
poly (I:C). Values are the mean ± SEM (n = 3 - 4). ***p < 0.001 compared with the values of vehicle-treated control. †††p < 0.001 compared with the
values of poly (I:C)-treated control
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H292 cells and primary HBECs and the potentiation is re-
versed by treatment with an antioxidant, NAC. In
addition, we demonstrated that NAC treatment decreased
the expression of IL-33 in HBECs from COPD patients,
but not in those from healthy subjects. These results sug-
gest that oxidative stress is involved in the expression of
IL-33 in airway epithelial cells. Previously, IL-33 has been
reported to be upregulated in human airway epithelial
cells by cigarette smoke exposure [11, 37]. As cigarette
smoke contains ROS including H2O2 [38, 39], cigarette
smoke-potentiated IL-33 expression is consistent with the
current findings. In the present study, we also demon-
strated that oxidative stress potentiates the amount of IL-
33 protein in the nucleus in airway epithelial cells. In a
previous study, Uchida M, et al. demonstrated that an
antioxidant, NAC or GSH, inhibits the alternaria extract-
augmented IL-33 release in an allergic mice model, and
they also demonstrated that NAC or GSH prevents extra-
cellular secretion of IL-33 from IL-33-overexpressed hu-
man bronchial epithelial cells exposed to alternaria
extract [24]. These reports support our current findings
that the expression of IL-33 is regulated by oxidative
stress.
H2O2 has been reported to activate not only the
MAPK signal pathway, but also the NF-κB signal path-
way in various cells including airway epithelial cells [23,
Fig. 5 Involvement of oxidative stress in the expression of IL-33 in HBECs from COPD patients. a Effect of H2O2-potentiated IL-33 expression and
reversal by NAC in human bronchial epithelial cells (HBECs) from healthy subjects. Cells were treated with NAC or vehicle prior to treatment with
H2O2. After 4 h, whole cells were harvested and assayed for the IL-33 gene expression. b Effect of NAC on the expression of IL-33 in HBECs from
healthy subjects and COPD patients. Cells were treated with NAC or vehicle. After 4 h, whole cells were harvested and assayed. The data are
expressed as the mean ± SEM of five healthy subjects or six COPD patients. c-e Effect of p38-MAPK inhibitor (SB203580), JNK inhibitor (SP600125)
or ERK inhibitor (U0126) on the expression of IL-33 in HBECs from COPD patients. Cells were treated with the MAPK inhibitor or vehicle. After 4 h,
whole cells were harvested and assayed. The data is a representative of two independent experiments with four samples performed using HBECs
from two COPD patients. **p < 0.01 compared with the values of vehicle-treated cells
Aizawa et al. Respiratory Research  (2018) 19:52 Page 8 of 12
28, 34]. In the present study, we clarified the involve-
ment of MAPK signal pathway in the mechanism of
H2O2-augmented IL-33 expression in airway epithelial
cells by showing the inhibitory effect of p38 MAPK, JNK
or ERK1/2 inhibitors. In addition, we demonstrated that
these inhibitors also decreased the expression of IL-33
in HBECs from COPD patients, which suggest that
MAPK signaling is involved in the regulation of IL-33
expression in airway epithelial cells in COPD. Using
murine alveolar epithelial cells or macrophage cells, the
involvement of the MAPK signal pathway has been dem-
onstrated in the IL-6 group of cytokines, oncostatin M-
or respiratory syncytial virus infection-augmented IL-33
expression and production [40, 41]. These reports sup-
port our current results. On the other hand, in our
present study, pretreatment with NF-κB inhibitors (an
IKK-2 inhibitor, SC-514, or an IκBα inhibitor, BAY 11-
7085) did not inhibit the H2O2-augmented IL-33 expres-
sion, suggesting that the NF-κB signal pathway is not in-
volved in the mechanism of H2O2-augmented IL-33
expression in airway epithelial cells. In murine mast
cells, IκB-α inhibitor (BAY11-7085) did not also inhibit
immunoglobulin E (IgE) activation-induced IL-33 ex-
pression [42], which is consistent with our results. How-
ever, in human corneal epithelial cells, cardiac cells or
murine bone marrow-derived dendritic cells, IκB-α
inhibitor (BAY11-7082) and NF-κB inhibitor (quinazo-
line or dimethylfumarate) was reported to block TLR li-
gands-, tumor necrosis factor alpha (TNF-α) or ragweed
pollen-potentiated IL-33 expression and production
[43–45]. These reports are inconsistent with our present
results. This discrepancy might result from differences
in the stimulating substance, in the cell types used or in
the experimental conditions including the inhibitor used.
In the present study, we showed that combination treat-
ment of H2O2 and a synthetic viral dsRNA analogue and a
TLR3 ligand, poly (I:C) or rhinovirus-infection signifi-
cantly increased the expression of IL-33 compared with
each treatment alone. Although the molecular mecha-
nisms by which H2O2 potentiates poly (I:C)- or
rhinovirus-induced IL-33 expression remain uncertain,
previous reports have proposed possible mechanisms.
TLR3 stimulation or rhinovirus infection has been dem-
onstrated to increase the expression of IL-33 in human
airway and corneal epithelial cells, and smooth muscle
cells [43, 46, 47]. In addition, the MAPK signal pathway
has been reported to be activated by TLR3 stimulation or
rhinovirus infection in human airway epithelial cells [28,
48, 49]. In our previous studies, we demonstrated that oxi-
dative stress enhances the expression of TLR3, and that
cigarette smoke potentiates TLR3-ERK signal pathway in
human airway epithelial cells [23, 27]. These results sug-
gest that the MAPK signal pathway is involved in the
H2O2-potentiated IL-33 expression induced by poly (I:C)
or rhinovirus infection. Recently, Hristova M, et al. have
reported that nicotinamide adenine dinucleotide phos-
phate (NADPH) oxidase homolog, dual oxidase 1
(DUOX1)-derived H2O2, is involved in the alternaria-in-
duced IL-33 release in airway epithelial cells. Activated
DUOX1-induced H2O2 has been shown to stimulate A
disintegrin and metalloproteinase 17 (ADAM17), which is
responsible for the shedding of EGFR pro-ligand and the
activation, and leads to the activation of the EGFR-ERK
signal pathway [50]. These reports may suggest that oxida-
tive stress augments the rhinovirus-stimulated IL-33 ex-
pression via TLR3-EGFR signal pathway. Further studies
are necessary to prove this hypothesis.
In the comparison of the expression of IL-33 in the
disease status of COPD, there was no increase in the ex-
pression of IL-33 in HBECs from COPD patients com-
pared to HBECs from healthy subjects, which is
inconsistent with a result previously reported that higher
expression of IL-33 appeared in the airway epithelial
cells from patients with COPD [10]. However, this
higher expression of IL-33 is shown in severe COPD in
GOLD stage IV. Another group has also reported that
an increase of the IL-33 protein level in the whole lung
appears only from severe COPD in GOLD stage III / IV
[11]. In our current study, all of the patients evaluated
were mild COPD in GOLD stage I-II, which might
Fig. 6 Schematic representation of the effect of oxidative stress
on IL-33 expression in airway epithelial cells. H2O2 potentiates
the expression of IL-33 in human airway epithelial cells. H2O2
enhances the phosphorylation of MAPK (p38, JNK, ERK1/2) and a
p38 MAPK inhibitor, SB203580, a JNK inhibitor, SP600125, and an
ERK1/2 inhibitor, U0126 inhibits the expression of IL-33. Neither
an IKK-2 inhibitor, SC-514 nor an IκBα inhibitor, BAY11-7085
affects the H2O2-augmented IL-33 expression. H2O2 potentiates
the expression of IL-33 stimulated by TLR3 ligand, poly (I:C)
and rhinoviral-infection, and the potentiation is inhibited by
the antioxidant NAC. These data suggest that oxidative stress
enhances the expression of IL-33 via MAPK pathway and the
expression of IL-33 can be further increased in human airway
epithelial cells during virus infections. NAC = N-acetylcysteine.
BAY = BAY 11-7085
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explain the discrepancy. In the current study, we also
showed that NAC treatment decreased the expression of
IL-33 in HBECs from COPD patients, but not in those
from healthy subjects, suggesting that oxidative stress is
involved in the expression of IL-33 in airway epithelial
cells in patients with COPD. We have previously re-
ported an increased level of oxidative stress in HBECs of
COPD patients compared to those in healthy subjects
[51] and, therefore, it could be thought that NAC treat-
ment decreased the increased level of oxidative stress in
the HBECs of COPD patients, which affects the expres-
sion of IL-33. However, there remains the discrepancy
that an increased level of oxidative stress is suggested in
the HBECs from COPD patients and NAC treatment de-
creased the IL-33 expression from the basal levels only
in COPD patients, but there is no increase in the expres-
sion of IL-33 in the HBECs from COPD patients com-
pared to healthy subjects. Several negative regulations of
IL-33 expression have been demonstrated, such as by
lipopolysaccharide treatment via TLR signaling in NCI-
H292 cells, or by one of short noncoding RNAs,
microRNA-487b in human monocytes [52, 53]. These
unknown negative regulatory mechanisms might affect
the expression of IL-33 in the airway epithelial cells of
COPD patients. Further studies are needed to clarify this
point.
As a limitation of the present study concerning
HBECs, there is a possibility that sex differences and
smoking status might affect the results because HBECs
were derived from 5 female healthy subjects and 1 fe-
male COPD patient. In addition, all of the healthy sub-
jects were non-smokers, whereas all of the COPD
patients were ex-smokers. Also, in the experiments in
HBECs from COPD patients and healthy subjects, the
evaluation of IL-33 expression was performed by meas-
uring the levels of mRNA expression and was not con-
firmed by examining the protein expression.
Conclusions
We demonstrated that oxidative stress is involved in the
expression of IL-33 in airway epithelial cells via the MAPK
signal pathway and that it augments IL-33 expression
during viral infection. This mechanism may participate in
the regulation of IL-33 expression in airway epithelial cells
in COPD and in viral-induced exacerbations. Modulation
of this pathway could be a therapeutic target for viral-
induced exacerbations of COPD.
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